BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37753656)

  • 21. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
    Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
    J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma.
    Mazur RD; Cron DC; Chang DC; Yeh H; Dageforde LAD
    Transplantation; 2024 Jan; 108(1):204-214. PubMed ID: 37189232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waitlist mortality and post-liver transplant outcomes of pediatric patients with hepatocellular carcinoma and hepatoblastoma in the United States.
    Wu WK; Ziogas IA; Matsuoka LK; Izzy M; Pai AK; Benedetti DJ; Alexopoulos SP
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29425. PubMed ID: 34736292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Accuracy of Nonstandardized MELD/PELD Score Exceptions in the Pediatric Liver Allocation System.
    Ahn DJ; Zeng S; Pelzer KM; Barth RN; Gallo A; Parker WF
    Transplantation; 2023 Oct; 107(10):e247-e256. PubMed ID: 37408100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Access to Liver Transplantation in Different ABO-Blood Groups and "Exceptions Points" in a Model for End-Stage Liver Disease Allocation System: A Brazilian Single-Center Study.
    Martino RB; Waisberg DR; Dias APM; Inoue VBS; Arantes RM; Haddad LBP; Rocha-Santos V; Pinheiro RSN; Nacif LS; D'Albuquerque LAC
    Transplant Proc; 2018 Apr; 50(3):754-757. PubMed ID: 29661430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
    Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
    J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver Transplantation in France.
    Durand F; Antoine C; Soubrane O
    Liver Transpl; 2019 May; 25(5):763-770. PubMed ID: 30697904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
    Alver SK; Lorenz DJ; Marvin MR; Brock GN
    Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
    Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
    Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.
    Croome KP; Lee DD; Harnois D; Taner CB
    PLoS One; 2017; 12(1):e0170673. PubMed ID: 28122003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
    Kensinger CD; Feurer ID; Karp SJ
    Transplantation; 2017 Sep; 101(9):2056-2061. PubMed ID: 28471871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.